Jennifer Haythe, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1649346958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Abbott at 26.9% of the total. 2025 is the largest year on record at $1,276, 6.2 times the $205 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NY, where the typical reported total is $5,971.
Across 127 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$948
- Novartis$772
- United Therapeutics Corporation$312
- Merck$280
- AstraZeneca$188
- Abiomed$136
- plus $892 from 15 others
Across 1 payment — averaging $29,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$30K
What the payments were for
- Food & beverage$3,41197%
- Education$1173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $948 |
| Novartis | 49 | $772 |
| United Therapeutics Corporation | 8 | $312 |
| Merck | 13 | $280 |
| AstraZeneca | 10 | $188 |
| Abiomed | 1 | $136 |
| Medtronic | 2 | $135 |
| Boehringer Ingelheim | 7 | $133 |
| Alnylam Pharmaceuticals Inc. | 5 | $112 |
| Cardiovascular Systems Inc. | 1 | $111 |
| Kestra Medical Technology Services, Inc. | 2 | $83 |
| Amgen | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Scpharmaceuticals Inc. | 1 | $37 |
| Gilead | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 2 | $32 |
| Bridgebio Pharma, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Pfizer | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$281
- CARDIOMEMS$159
- THORATEC HEARTMATE 3$151
- Impella$136
- HeartMate 3 Left Ventricular Assist Device$112
- COREVALVE EVOLUT R$111
- Coronary Orbital Atherectomy System$111
How this compares
$3,528 in reported general payments places this provider in the 30th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 18 | $316,735 |
| AdempasRiociguat | 14 | $193,156 |
| Ambrisentan | 31 | $79,369 |
| JardianceEmpagliflozin | 36 | $55,616 |
| EntrestoSacubitril/Valsartan | 45 | $54,178 |
| FarxigaDapagliflozin Propanediol | 21 | $21,894 |
| Sildenafil Citrate | 30 | $21,891 |
| EliquisApixaban | 23 | $18,274 |
| Torsemide | 46 | $1,267 |
| Metoprolol Succinate | 51 | $1,193 |
| Carvedilol | 27 | $269 |
| Furosemide | 45 | $222 |
| Spironolactone | 50 | $191 |
| Amlodipine Besylate | 29 | $115 |
| Losartan Potassium | 16 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $133 | $55,61636 claims |
| NovartisEntresto | $772 | $54,17845 claims |
| AstraZenecaFarxiga | $188 | $21,89421 claims |
| PfizerEliquis | $17 | $18,27423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.